SC 13G/A | 2022-02-14 | Omega Fund IV, L.P. | Replimune Group, Inc. | 5,012,052 | 10.6% | EDGAR |
SC 13G/A | 2022-02-09 | FMR LLC | Replimune Group, Inc. | 1,054,119 | 2.2% | EDGAR |
SC 13G/A | 2021-07-12 | PRICE T ROWE ASSOCIATES INC /MD/ | Replimune Group, Inc. | 5,069,450 | 10.8% | EDGAR |
SC 13G/A | 2021-02-16 | Coffin Robert | Replimune Group, Inc. | 2,307,300 | 4.9% | EDGAR |
SC 13G/A | 2021-02-16 | Redmile Group, LLC | Replimune Group, Inc. | 4,658,043 | 9.9% | EDGAR |
SC 13G/A | 2021-02-16 | Forbion Capital Fund III Cooperatief U.A. | Replimune Group, Inc. | 5,115,121 | 11.1% | EDGAR |
SC 13G/A | 2021-02-16 | Bain Capital Life Sciences Fund, L.P. | Replimune Group, Inc. | 0 | 0.0% | EDGAR |
SC 13G | 2021-02-16 | PRICE T ROWE ASSOCIATES INC /MD/ | Replimune Group, Inc. | 2,625,691 | 5.7% | EDGAR |
SC 13G/A | 2021-02-11 | BIOTECHNOLOGY VALUE FUND L P | Replimune Group, Inc. | - | 0.0% | EDGAR |
SC 13G | 2021-02-08 | FMR LLC | Replimune Group, Inc. | 2,626,417 | 5.7% | EDGAR |
SC 13D/A | 2020-09-17 | Atlas Venture Fund X, L.P. | Replimune Group, Inc. | 2,486,296 | 6.2% | EDGAR |
SC 13D/A | 2020-07-07 | Atlas Venture Fund X, L.P. | Replimune Group, Inc. | 2,931,635 | 7.4% | EDGAR |
SC 13D/A | 2020-06-19 | Atlas Venture Fund X, L.P. | Replimune Group, Inc. | 3,376,974 | 8.6% | EDGAR |
SC 13G/A | 2020-02-14 | BIOTECHNOLOGY VALUE FUND L P | Replimune Group, Inc. | 1,135,306 | 3.2% | EDGAR |
SC 13G/A | 2020-02-14 | Foresite Capital Fund III, L.P. | Replimune Group, Inc. | 313,922 | 0.8% | EDGAR |
SC 13G/A | 2020-02-14 | Coffin Robert | Replimune Group, Inc. | 2,541,427 | 6.9% | EDGAR |
SC 13G/A | 2020-02-14 | Redmile Group, LLC | Replimune Group, Inc. | 3,621,635 | 9.9% | EDGAR |
SC 13G/A | 2020-02-14 | Omega Fund IV, L.P. | Replimune Group, Inc. | 5,323,455 | 16.5% | EDGAR |
SC 13G/A | 2020-02-11 | Forbion Capital Fund III Cooperatief U.A. | Replimune Group, Inc. | 5,115,121 | 14.4% | EDGAR |
SC 13D | 2019-11-25 | Atlas Venture Fund X, L.P. | Replimune Group, Inc. | 3,822,213 | 10.8% | EDGAR |